Latest news

• Gilead and Galapagos JAK contender scores in RA trial

  Another player is Lilly’s Olumiant, though this is held back by safety concerns.

• Gilead, Galapagos JAK inhibitor clears phase II test

  DVT is a recognised side effect with Eli Lilly’s JAK1 inhibitor Olumiant (baricitinib), which finally made it to market for rheumatoid arthritis in Europe last year but was rejected in ... related. First-to-market JAK inhibitor Xeljanz (tofacitinib)

• GSK sells eczema and psoriasis drug to Dermavant for £250m

  s Xeljanz (tofacitinib) and Incyte/Eli Lilly’s Olumiant (baricitinib).

• Another R&D flop for Incyte, but Jakafi keeps delivering

  Nevertheless, it’s another bit of bad news for Incyte after the epacadostat failure, what looks likely to be reduced royalties from Eli Lilly for rheumatoid arthritis JAK inhibitor Olumiant (baricitinib)

• AbbVie builds case for arthritis blockbuster-in-waiting upadacitinib

  be an under-estimate given that a third JAK inhibitor - Eli Lilly and Incyre’s Olumiant (baricitinib) - has been dogged by regulatory problems. ... Olumiant was finally approved by the FDA for RA a couple of weeks ago, but has been saddled with a black